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Clinical background
Brazil stands out among developing countries due to its
program of universal access to antiretroviral drugs and
clinical care exams. According to the national guidelines,
women initiating ART during pregnancy for the preven-
tion of MTCT of HIV who do not otherwise meet the
requirements for continued receipt of therapy discontinue
ART after delivery [1]. There are significant concerns that
this strategy could jeopardize future treatment options for
these women [2]. The objective of the present study was to
evaluate the impact of treatment discontinuation follow-
ing delivery for the emergence of genotypic resistance.
Patients and methods
Since January 2005, a prospective cohort of HIV infected
pregnant women, identified during prenatal care visits
have been established at Hospital Geral de Nova Iguaçu,
RJ. Antiretroviral prophylaxis with HAART was adopted
for the prevention of HIV vertical transmission. Clinical
and laboratory parameters, such as flow cytometry for
CD4 counts, HIV-RNA levels (Nuclisens, Biomerieux) and
genotyping (ViroSeq, Celera-Abbott), were determined at
baseline and follow-up visits (6-8weeks after HAART, at
delivery and postpartum [15 days, 1, 6 and 12 months]).
Results
Until August 2007, 195 women ARV naïve and their
babies have been enrolled and followed. Data from the
first 120 ARV naïve pregnant women have already been
analyzed. The median age was 26 years (SD=6.6); 72% of
the women were non white and the median gestational
age at prenatal care initiation was 26 weeks (IQR, 20-31).
The median CD4 cell count at baseline was 439.5 cells/
mm3 (IQR, 300–586) and VL was 3.91 log10 (IQR, 3.22–
4.46). 25% of the women received a NVP-based ARV reg-
imen (ZDV, 3TC and NVP) and 75% have received a
Nelfinavir based ARV regimen (ZDV, 3TC, and NFV). The
median time on ART was 75 days (IQR, 42–107). The
median VL reduction between 6-8 weeks following initia-
tion of ART was 2.01 log10 copies/ml. 64.2% (43/67) of
women achieved undetectable VL (< 80 copies/ml) and
89.5% (60/67) had less than 1,000 copies/ml at the time
of delivery. 76% (56/74) of women had a cesarean section
delivery and 24% (18/74) had a vaginal delivery.
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No cases of MTCT of HIV been reported so far. Low levels
(<5%) of drug resistance have been detected until now at
baseline and after ARV. HIV-1 infections were due to sub-
types B (78%), F (8%) and BF (10%), BD (3%) and BC
(1%) recombinant viruses. From this naïve cohort, 8.6%
(17/194) became pregnant within the first year of follow
up after their delivery.
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